Rational prescribing of acid-suppressive therapy requires an understanding of how gastric acid secretion is regulated at the parietal cell level. Three receptor systems converge on the H+/K+-adenosine triphosphatase (H/K-ATPase) as the final common effector, and the pharmacology of acid suppression is in large part the pharmacology of selectively interrupting these converging signals at their most effective point.
The parietal cell is the acid-secreting cell of the gastric oxyntic mucosa. Its basolateral membrane carries three distinct receptor types that stimulate acid secretion through separate but converging intracellular pathways. The H2R (histamine H2 receptor) is a Gs-coupled receptor whose activation by histamine released from ECL (enterochromaffin-like) cells raises intracellular cAMP (cyclic adenosine monophosphate), activating PKA (protein kinase A) and ultimately driving translocation of H/K-ATPase-bearing tubulovesicles to the apical canalicular membrane. The M3R (muscarinic M3 receptor) is a Gq-coupled receptor whose activation by vagal acetylcholine raises intracellular calcium, acting synergistically with the cAMP pathway. The gastrin receptor, specifically the CCK-BR (cholecystokinin B receptor), responds to gastrin released from antral G cells and activates both calcium-dependent pathways and stimulates ECL cells to release additional histamine, creating a paracrine amplification loop.1 The histamine pathway is quantitatively dominant in humans, which explains why H2RAs (H2 receptor antagonists) are effective acid suppressants despite not blocking muscarinic or gastrin receptors directly.
The H/K-ATPase is an electroneutral proton pump located on tubulovesicles within the parietal cell cytoplasm in the resting state. Upon stimulation, these vesicles fuse with the apical canalicular membrane, greatly expanding the secretory surface area and inserting active proton pumps into direct contact with the gastric lumen. The pump exchanges one intracellular H+ for one luminal K+ per catalytic cycle, using one molecule of ATP (adenosine triphosphate) per exchange. This process drives luminal pH down to values approaching 1.0, representing an approximately one-million-fold concentration gradient for protons across the canalicular membrane. The K+ required for pump function is supplied by KCNQ1 (potassium voltage-gated channel subfamily Q member 1) and KCNE2 (potassium voltage-gated channel subfamily E member 2) channels on the apical membrane and is recycled, so net acid secretion results in chloride secretion as HCl without permanent potassium depletion.2 Understanding this pump mechanism is essential to understanding why PPIs (proton pump inhibitors) require activation in the acidic canalicular environment and why their onset of action is delayed relative to H2RAs.
The cephalic, gastric, and intestinal phases of acid secretion each activate this system through different afferent signals. The cephalic phase, mediated by vagal stimulation in response to the sight, smell, and anticipation of food, activates M3R on parietal cells and stimulates ECL cell histamine release. The gastric phase is triggered by gastric distension and luminal protein content, with distension activating vagovagal reflexes and protein fragments directly stimulating gastrin release from G cells. The intestinal phase, driven by amino acids and fatty acids entering the duodenum, contributes a modest additional secretory drive. The net result is a meal-stimulated acid secretory response that peaks approximately one to two hours after eating. This temporal pattern is relevant to PPI (proton pump inhibitor) dosing, as PPIs are only active against pumps that are actively secreting at the time of drug exposure, making pre-meal dosing essential for maximal efficacy.1
Histamine released from ECL (enterochromaffin-like) cells acts not only directly on parietal cell H2R (histamine H2 receptor) but also amplifies the response to gastrin and acetylcholine. Gastrin stimulates ECL cells to release histamine, and acetylcholine enhances both ECL cell histamine release and direct parietal cell M3R (muscarinic M3 receptor) activation. This convergence makes histamine the final common paracrine mediator for all three stimulatory pathways, which is why H2RAs (H2 receptor antagonists) blunt the response to all three stimuli, not just to exogenous histamine. PPIs (proton pump inhibitors) act downstream of all receptor signaling at the pump itself, providing even more complete suppression regardless of which stimulus initiated acid secretion.
PPI (proton pump inhibitor) agents are substituted benzimidazoles that function as irreversible inhibitors of the H/K-ATPase. All currently available PPIs, including omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole, share the same mechanism: they are prodrugs that require activation in the highly acidic environment of the secretory canaliculus. At canalicular pH of approximately 1.0, the prodrug undergoes acid-catalyzed conversion to a reactive sulfenamide intermediate, which then forms a covalent disulfide bond with a cysteine residue on the luminal surface of the alpha subunit of H/K-ATPase, irreversibly inactivating the pump.3 Because only actively secreting pumps have access to the canalicular space, PPIs can only inactivate pumps that are turned on at the time of drug exposure. New acid secretion requires synthesis of new H/K-ATPase protein, which takes approximately 18 hours, explaining why the duration of acid suppression outlasts the plasma half-life of the drug by many hours.
The pharmacokinetic implications of this mechanism are clinically significant. PPIs must be administered in enteric-coated or delayed-release formulations to survive gastric passage intact, be absorbed in the small intestine, and then concentrate in the canaliculus when parietal cells are actively secreting. This is why all oral PPIs must be taken 30 to 60 minutes before a meal: pre-meal dosing ensures that peak plasma concentrations coincide with maximal parietal cell stimulation by food, maximizing the proportion of H/K-ATPase available for inhibition. A PPI taken with or after a meal encounters fewer active pumps and produces substantially less acid suppression than the same dose taken before eating.3 On the first day of dosing, PPIs suppress only 60 to 70% of pump capacity because a proportion of pumps remain in the resting tubulovesicular pool; steady-state suppression of 90 to 95% is achieved after 3 to 5 days of daily dosing as the resting pool is progressively depleted.
All PPIs are metabolized primarily by CYP2C19 (cytochrome P450 2C19), with CYP3A4 (cytochrome P450 3A4) as a secondary pathway. CYP2C19 is highly polymorphic with clinically important phenotypic consequences. UM (ultrarapid metabolizers), who carry CYP2C19 gain-of-function alleles (*17/*17), clear PPIs so rapidly that standard doses may produce inadequate acid suppression, and this pharmacogenomic variant is a recognized contributor to treatment failure in H. pylori (Helicobacter pylori) eradication regimens. PM (poor metabolizers), who carry two loss-of-function alleles such as *2/*2 or *2/*3, have two- to five-fold higher PPI plasma exposures at standard doses and achieve substantially greater acid suppression, which may be advantageous in H. pylori eradication but poses a modest risk of increased adverse effects with long-term use.4 Among available PPIs, rabeprazole is metabolized predominantly by non-enzymatic reduction rather than by CYP2C19, making it the least susceptible to CYP2C19 polymorphism. Esomeprazole, the S-enantiomer of omeprazole, has somewhat reduced CYP2C19 metabolism and modestly less variable exposure.
The drug interaction profile of PPIs reflects both their CYP2C19 metabolism and their potent acid suppression. The most clinically debated interaction is between omeprazole and clopidogrel. Clopidogrel is a prodrug requiring CYP2C19 activation to its active thiol metabolite; omeprazole and esomeprazole inhibit CYP2C19, and co-administration reduces clopidogrel active metabolite exposure and platelet inhibition in pharmacokinetic studies. Despite this pharmacokinetic interaction being well established, outcomes data from large trials including COGENT (Clopidogrel and the Optimization of Gastrointestinal Events Trial) have not demonstrated an increase in major cardiovascular events with concomitant PPI use, while GI (gastrointestinal) bleeding risk was substantially reduced.5 Pantoprazole has minimal CYP2C19 inhibitory activity and is preferred when a PPI is needed in a patient on clopidogrel who is not at high GI bleeding risk.
PPIs also raise intragastric pH sufficiently to impair absorption of drugs requiring an acidic environment for dissolution, including atazanavir, whose absorption is strongly pH-dependent, as well as rilpivirine, ketoconazole, and iron salts. PPIs reduce methotrexate renal tubular secretion, increasing methotrexate exposure and toxicity risk at high doses. Hypomagnesemia is a well-documented adverse effect of long-term PPI use, arising from impaired magnesium absorption through TRPM6 (transient receptor potential melastatin 6) and TRPM7 (transient receptor potential melastatin 7) channels in the small intestine, whose activity depends on luminal acidity.6 Clinically significant hypomagnesemia can cause tetany, seizures, and refractory cardiac arrhythmias, and does not correct with oral magnesium supplementation because the intestinal absorption defect persists; stopping the PPI is required. Serum magnesium monitoring is warranted in patients on long-term PPIs, particularly those taking digoxin or antiarrhythmic drugs.
An increased risk of C. difficile (Clostridioides difficile) infection with PPI use is supported by multiple epidemiological studies; the proposed mechanism is that gastric acid normally destroys ingested C. difficile organisms, and acid suppression allows greater survival and colonic colonization.7 Long-term PPI use has also been associated with an increased risk of hip, wrist, and spine fractures in observational studies, attributed to impaired calcium absorption; calcium citrate, which does not require acid for dissolution, is preferred over calcium carbonate for supplementation in PPI users. Rebound acid hypersecretion occurs on PPI discontinuation because chronic acid suppression leads to hypergastrinemia-driven ECL (enterochromaffin-like) cell hyperplasia, causing a transient period of excess acid lasting one to two weeks after stopping. Gradual tapering or step-down to an H2RA (H2 receptor antagonist) is preferable to abrupt discontinuation in patients on long-term therapy.
Hypomagnesemia: check serum magnesium at baseline and annually in patients on long-term PPIs (proton pump inhibitors), especially those on digoxin or antiarrhythmics. Oral magnesium does not correct PPI-induced hypomagnesemia because the intestinal TRPM6 (transient receptor potential melastatin 6) channel defect persists; stopping the PPI is required. Fracture risk: recommend calcium citrate over calcium carbonate for supplementation. C. difficile (Clostridioides difficile) risk: avoid prescribing PPIs without a clear indication, particularly in hospitalized patients. Rebound hypersecretion: taper rather than abruptly stop long-term PPIs.
A PPI (proton pump inhibitor) taken 30 to 60 minutes before the first meal of the day achieves maximum acid suppression because the meal stimulates maximal parietal cell activation, exposing the greatest proportion of H/K-ATPase to canalicular acid and thus to the activated PPI sulfenamide. A PPI taken at bedtime or with food suppresses significantly less acid. For twice-daily regimens used in H. pylori (Helicobacter pylori) eradication, the second dose should be taken 30 to 60 minutes before the evening meal, not at bedtime. Correct timing is among the most commonly missed prescribing details for PPIs and is a correctable source of treatment failure.
The H2RA (H2 receptor antagonist) class competitively and reversibly blocks the H2R (histamine H2 receptor) on the basolateral membrane of parietal cells, reducing both basal and meal-stimulated acid secretion. Unlike PPI (proton pump inhibitor) agents, which irreversibly inactivate H/K-ATPase already inserted in the canalicular membrane, H2RAs block an upstream signaling step; because the block is competitive and reversible, acid secretion recovers as histamine concentrations rise above the level that the administered H2RA dose can competitively displace. H2RAs reduce 24-hour intragastric acidity by approximately 60 to 70%, compared with PPIs at 90 to 95%, reflecting this mechanistic difference. H2RAs are more effective at suppressing nocturnal acid secretion, which is histamine-driven and relatively independent of meals, than postprandial acid secretion, which has a stronger gastrin and acetylcholine component. This makes H2RAs particularly useful for patients with nocturnal symptoms or for supplementing PPIs in patients with documented nocturnal acid breakthrough.8
The four H2RAs that reached clinical practice were cimetidine, ranitidine, famotidine, and nizatidine. Ranitidine was withdrawn globally in 2020 due to contamination with NDMA (N-nitrosodimethylamine), an impurity that forms from ranitidine degradation and accumulates with storage at elevated temperatures; it is no longer available. Cimetidine, the first H2RA introduced, is now rarely used in clinical practice due to its extensive drug interaction profile arising from broad inhibition of CYP (cytochrome P450) isoforms: cimetidine inhibits CYP1A2 (cytochrome P450 1A2), CYP2C9 (cytochrome P450 2C9), CYP2D6 (cytochrome P450 2D6), and CYP3A4 (cytochrome P450 3A4), raising plasma concentrations of theophylline, warfarin, phenytoin, tricyclic antidepressants, and many other medications to potentially toxic levels. Cimetidine also blocks renal tubular secretion of creatinine, raising serum creatinine without affecting the GFR (glomerular filtration rate), and blocks androgen receptors at higher doses, producing gynecomastia and sexual dysfunction in men.
Famotidine is the preferred H2RA in current practice: it has minimal CYP inhibitory activity, no significant anti-androgenic effects, and a favorable renal excretion pharmacokinetic profile. Dose reduction is required in patients with reduced GFR, as famotidine is predominantly renally excreted unchanged. Nizatidine shares famotidine's favorable interaction profile and is still available in some markets. For any clinical indication requiring an H2RA, famotidine is the appropriate choice whenever cimetidine is under consideration.
Tolerance (tachyphylaxis) is a clinically significant limitation of H2RAs with continuous dosing. After 1 to 2 weeks of continuous H2RA administration, acid suppression is substantially reduced compared with the first dose, with most of the tolerance effect attributable to hypergastrinemia-driven ECL (enterochromaffin-like) cell proliferation and upregulation of H2R (histamine H2 receptor) expression on parietal cells. The magnitude of the tolerance effect is most pronounced with continuous intravenous infusion. For this reason, H2RAs are not recommended for long-term maintenance acid suppression when a PPI (proton pump inhibitor) is available; their most appropriate current roles include short-term symptom relief, on-demand use for breakthrough symptoms in patients on PPIs, supplementing PPIs to address nocturnal acid breakthrough, and use in patients who cannot tolerate PPIs. Famotidine is also used for stress ulcer prophylaxis in severely ill patients with coagulopathy or mechanical ventilation, where some intensivists prefer the intravenous H2RA route over intravenous PPIs due to concerns about PPI-associated C. difficile and ventilator-associated pneumonia risk, though the evidence remains debated.8
Cimetidine and famotidine are both H2RAs (H2 receptor antagonists) with equivalent acid suppression per milligram-equivalent dose, but their safety profiles differ markedly. Cimetidine inhibits CYP1A2 (cytochrome P450 1A2), CYP2C9 (cytochrome P450 2C9), CYP2D6 (cytochrome P450 2D6), and CYP3A4 (cytochrome P450 3A4), raising levels of warfarin, theophylline, phenytoin, and many other drugs. It also blocks androgen receptors, causing gynecomastia and impotence at higher doses. Famotidine has negligible CYP inhibition, no anti-androgenic effects, and a predictable renal excretion profile. There is no clinical scenario in which cimetidine is preferred over famotidine.
Helicobacter pylori (H. pylori) is a gram-negative microaerophilic spiral bacterium that colonizes the gastric mucosa in approximately half the world's population, causing chronic active gastritis, PUD (peptic ulcer disease), and carrying a 1 to 2% lifetime risk of gastric adenocarcinoma and MALT (mucosa-associated lymphoid tissue) lymphoma in colonized individuals. Eradication of H. pylori heals peptic ulcers, reduces ulcer recurrence from approximately 80% per year to less than 10%, and is recommended for all patients with confirmed H. pylori infection regardless of symptoms, per current ACG (American College of Gastroenterology) guidelines.9 The choice of eradication regimen must account for local clarithromycin resistance rates, prior macrolide exposure in the individual patient, and CYP2C19 (cytochrome P450 2C19) metabolizer status when PPI (proton pump inhibitor)-based regimens are used.
Standard triple therapy, consisting of a PPI twice daily plus amoxicillin 1 g twice daily plus clarithromycin 500 mg twice daily for 14 days, remains a recommended first-line regimen in regions where clarithromycin resistance rates are below 15%, but eradication rates have declined substantially in regions with higher resistance. Clarithromycin resistance, mediated by mutations in the 23S rRNA (ribosomal RNA) gene that prevent macrolide binding, now exceeds 15% in many urban areas of the United States and Europe, rendering standard triple therapy unacceptably ineffective in those settings.9 Bismuth quadruple therapy, consisting of a PPI twice daily plus bismuth subcitrate or subsalicylate four times daily plus metronidazole 500 mg three to four times daily plus tetracycline 500 mg four times daily for 10 to 14 days, achieves eradication rates above 90% regardless of clarithromycin resistance status and is recommended as a preferred first-line regimen in areas with high clarithromycin resistance or when prior macrolide exposure is documented.
CYP2C19 metabolizer status affects H. pylori eradication outcomes because the degree of acid suppression achieved by the PPI component is a critical determinant of antibiotic efficacy. Antibiotics are significantly less active at low gastric pH, and the intragastric antibiotic concentration required for bactericidal activity against H. pylori is only achievable when luminal pH is maintained above 6 for a sufficient proportion of the 24-hour period. UM (ultrarapid CYP2C19 metabolizers) achieve lower PPI plasma concentrations and less sustained acid suppression, resulting in lower eradication rates with standard PPI doses. In clinical practice, this is addressed by using higher PPI doses, such as esomeprazole 40 mg twice daily rather than 20 mg twice daily, in known ultrarapid metabolizers, or by selecting rabeprazole, which is least sensitive to CYP2C19 variability, as the PPI component of the eradication regimen.4
Levofloxacin-based salvage therapy, consisting of a PPI twice daily plus amoxicillin 1 g twice daily plus levofloxacin 500 mg once daily for 14 days, is recommended as second-line therapy after failure of bismuth quadruple therapy or in penicillin-allergic patients. Fluoroquinolone resistance in H. pylori has been increasing and must be considered before empirical levofloxacin-based salvage. For patients failing two prior eradication attempts, rifabutin-based therapy using a PPI twice daily plus amoxicillin 1 g twice daily plus rifabutin 150 mg twice daily for 10 days is an option. Rifabutin is a rifamycin antibiotic with very low H. pylori resistance rates globally, though its use is reserved for salvage contexts due to cost, myelotoxicity risk, and concern about selecting for rifamycin-resistant mycobacteria.9
Diagnostic testing for H. pylori should follow a test-and-treat strategy. Non-invasive testing is appropriate for most patients under age 60 without alarm features such as dysphagia, unintentional weight loss, evidence of GI (gastrointestinal) bleeding, or prior gastric surgery or malignancy. The UBT (urea breath test) exploits H. pylori urease activity: the patient ingests labeled urea (C13 or C14), and H. pylori urease hydrolyzes it to labeled carbon dioxide, which is detected in exhaled breath. The UBT has sensitivity and specificity above 95% and is the preferred non-invasive test for both diagnosis and post-treatment confirmation of eradication. The H. pylori SAT (stool antigen test) is an acceptable alternative with comparable accuracy, using monoclonal antibody detection of H. pylori antigen in stool. Both the UBT and SAT can yield false-negative results if performed within 2 weeks of PPI use or within 4 weeks of antibiotic or bismuth use; PPIs must be withheld for 2 weeks before testing. Serology does not distinguish active from past infection and should not be used to confirm active infection or eradication.10
Early H. pylori eradication trials used 7-day regimens, which achieved acceptable results when clarithromycin resistance was uncommon. Meta-analyses consistently show that extending standard triple therapy from 7 to 14 days increases eradication rates by 5 to 10 percentage points, a clinically meaningful improvement when background resistance rates are already reducing efficacy. Both ACG (American College of Gastroenterology) guidelines and the Maastricht V/Florence consensus recommend 14-day duration for all H. pylori eradication regimens. Prescribing a 7-day course to reduce cost or improve adherence is not justified by the evidence and risks treatment failure with consequent antibiotic resistance selection.
Both the UBT (urea breath test) and SAT (stool antigen test) require active H. pylori metabolic activity to generate a positive result. PPIs (proton pump inhibitors) suppress H. pylori activity and must be stopped for at least 2 weeks before testing. Antibiotics and bismuth must be stopped for at least 4 weeks before testing. Failure to observe these washout periods is the most common cause of false-negative tests in clinical practice. Serology is unaffected by PPIs or antibiotics but cannot confirm eradication because antibody titers remain elevated for months to years after successful treatment.
Antacids are aluminum, magnesium, or calcium salts that directly neutralize luminal HCl (hydrochloric acid) through a buffering reaction, raising intragastric pH and transiently reducing the proteolytic activity of pepsin, which is inactive above pH 4. Aluminum hydroxide reacts with HCl to form aluminum chloride and water, and is constipating; magnesium hydroxide similarly reacts to form magnesium chloride and water, and is laxative; combination aluminum-magnesium preparations balance these opposing GI (gastrointestinal) effects. Calcium carbonate is rapidly effective but generates carbon dioxide gas causing belching, and its calcium load can lead to the milk-alkali syndrome with excessive chronic use. All antacids have a short duration of action of 1 to 2 hours when taken on an empty stomach, as they are diluted and emptied with gastric contents; they are most effective when taken 1 to 2 hours after meals, when gastric acid secretion is maximal and gastric emptying is slowed. The clinical role of antacids is largely limited to on-demand symptom relief for mild intermittent heartburn. Clinically significant drug interactions occur when antacids are taken simultaneously with fluoroquinolones, tetracyclines, iron salts, and bisphosphonates, which chelate with polyvalent cations and form non-absorbable complexes; these drugs should be administered at least 2 hours before or 4 to 6 hours after antacid use.
Sucralfate is an aluminum salt of sucrose octasulfate that exerts cytoprotective effects through several complementary mechanisms rather than acid neutralization. At gastric pH below 4, sucralfate polymerizes into a viscous paste that selectively adheres to positively charged proteins at the base of ulcer craters and areas of damaged mucosa, forming a physical barrier that protects the ulcer from acid, pepsin, and bile for up to 6 hours per dose. Sucralfate also stimulates PGE2 (prostaglandin E2) synthesis in the gastric mucosa, stimulates mucus and bicarbonate secretion, and binds bile acids and pepsin, reducing their ulcerogenic activity.11 Sucralfate contains approximately 200 mg of aluminum per gram of drug; systemic aluminum absorption is minimal in patients with normal renal function but accumulates to clinically relevant concentrations in patients with CKD (chronic kidney disease), in whom sucralfate should be avoided or used with great caution.
Sucralfate is effective as a stress ulcer prophylactic in ventilated patients and has been associated in some trials with a lower incidence of ventilator-associated pneumonia than H2RA (H2 receptor antagonist) drugs or PPI (proton pump inhibitor) agents, attributed to its lack of effect on intragastric pH and thus reduced risk of gastric bacterial overgrowth. Drug interactions with sucralfate are clinically significant: it reduces the absorption of fluoroquinolones, phenytoin, warfarin, digoxin, and thyroid hormone when administered simultaneously, and a minimum 2-hour separation is required for all these agents.
Misoprostol is a synthetic PGE1 (prostaglandin E1) analog that exerts cytoprotective effects through EP1 (prostaglandin E receptor subtype 1) and EP3 (prostaglandin E receptor subtype 3) on parietal cells and gastric mucosal cells. Endogenous prostaglandins, particularly PGE2 and PGI2 (prostacyclin), are critical mediators of gastric mucosal defense, stimulating mucus and bicarbonate secretion, enhancing mucosal blood flow, and inhibiting acid secretion via EP3 receptors on parietal cells. NSAIDs (non-steroidal anti-inflammatory drugs) inhibit COX-1 (cyclo-oxygenase 1) and COX-2 (cyclo-oxygenase 2), suppressing the synthesis of these protective prostaglandins; gastric mucosal NSAID (non-steroidal anti-inflammatory drug) toxicity is predominantly a consequence of this systemic loss of prostaglandin-mediated mucosal protection rather than topical acid injury from the drug itself, which is why enteric coating of NSAIDs does not prevent ulcer formation.12 Misoprostol 200 mcg four times daily reduces the incidence of NSAID-induced gastric and duodenal ulcers by approximately 40%, making it a pharmacologically logical choice for gastroprotection in patients who require chronic NSAID therapy and cannot take a PPI (proton pump inhibitor). Its clinical adoption for this indication has been limited by dose-dependent diarrhea and abdominal cramping, the principal reason patients discontinue the drug.
Misoprostol's absolute contraindication in pregnancy is among the most important safety rules in clinical pharmacology. PGE1 analogs stimulate myometrial contractions through uterine EP (prostaglandin E) receptors and ripen the cervix by promoting collagen dissolution. Misoprostol, even at low gastroprotective doses, can induce uterine contractions sufficient to cause first-trimester miscarriage or second- and third-trimester preterm labor. The drug has been used intentionally for cervical ripening, labor induction, and combined with mifepristone for medical termination of pregnancy; this known uterotonic action makes inadvertent exposure in an unrecognized pregnancy a serious risk. Misoprostol should not be prescribed to women of childbearing potential without confirmed negative pregnancy status and reliable contraception, and carries an FDA (U.S. Food and Drug Administration) Pregnancy Category X designation. This contraindication must be communicated explicitly and documented when prescribing misoprostol for any indication.13
Misoprostol stimulates uterine contractions through PGE1 (prostaglandin E1) receptor activation on myometrium and is used intentionally in obstetrics for cervical ripening and labor induction. Even the gastroprotective dose of 200 mcg four times daily is sufficient to cause first-trimester miscarriage or premature labor. Before prescribing misoprostol for NSAID (non-steroidal anti-inflammatory drug) gastroprotection, confirm the absence of pregnancy and ensure reliable contraception. The FDA (U.S. Food and Drug Administration) Pregnancy Category X designation reflects a risk that unambiguously outweighs any gastroprotective benefit in a pregnant patient. Document this discussion in the medical record. PPI (proton pump inhibitor)-based gastroprotection is uniformly preferred in women of childbearing potential.
PPIs are first-line for erosive esophagitis, peptic ulcer disease, H. pylori eradication, NSAID gastroprotection, and Zollinger-Ellison syndrome. Take 30 to 60 minutes before the first meal of the day.
H2RAs (famotidine) are appropriate for mild intermittent symptoms, nocturnal acid breakthrough supplementation, stress ulcer prophylaxis in ICU patients when PPI concerns apply, and patients intolerant of PPIs. Tachyphylaxis limits long-term efficacy.
Sucralfate is a preferred stress ulcer prophylactic in ventilated patients where minimizing intragastric pH elevation is a priority. Avoid in advanced CKD (chronic kidney disease) due to aluminum accumulation. Separate from other drugs by 2 hours.
Misoprostol is a pharmacologically logical NSAID gastroprotective agent limited in practice by GI tolerability and absolutely contraindicated in pregnancy. Use PPI-based NSAID gastroprotection preferentially in women of childbearing potential.
Antacids provide rapid but short-lived symptom relief only. No role in ulcer healing or long-term management.
Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology. 2008;134(7):1842–1860.
doi:10.1053/j.gastro.2008.05.021Sachs G, Shin JM, Vagin O, Lambrecht N, Yakubov I, Munson K. The gastric H,K ATPase as a drug target: past, present, and future. J Clin Gastroenterol. 2007;41(Suppl 2):S226–S242.
doi:10.1097/MCG.0b013e31803233b7Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10(6):528–534.
doi:10.1007/s11894-008-0098-4Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Drug Metab Pharmacokinet. 2005;20(3):153–167.
doi:10.2133/dmpk.20.153Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909–1917.
doi:10.1056/NEJMoa1007964Cundy T, Mackay J. Proton pump inhibitors and severe hypomagnesaemia. Curr Opin Gastroenterol. 2011;27(2):180–185.
doi:10.1097/MOG.0b013e32833ff5d6Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107(7):1011–1019.
doi:10.1038/ajg.2012.108Young PJ, Bagshaw SM, Forbes AB, et al.; PEPTIC Investigators. Effect of stress ulcer prophylaxis with proton pump inhibitors vs histamine-2 receptor blockers on in-hospital mortality among ICU patients receiving invasive mechanical ventilation: the PEPTIC randomized clinical trial. JAMA. 2020;323(7):616–626.
doi:10.1001/jama.2019.22190Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212–239.
doi:10.1038/ajg.2016.563Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30.
doi:10.1136/gutjnl-2016-312288Tarnawski A, Hollander D, Stachura J, Krause WJ, Eltorai M, Dabros W, Gergely H. Pathways of gastrointestinal protection and repair: mechanisms of action of sucralfate. Am J Med. 1989;86(6A):125–131.
doi:10.1016/0002-9343(89)90153-8Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet. 1988;2(8623):1277–1280.
doi:10.1016/S0140-6736(88)92892-3Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet. 2007;99(Suppl 2):S160–S167.
doi:10.1016/j.ijgo.2007.09.004